Zobrazeno 1 - 10
of 78
pro vyhledávání: '"Erik de Blois"'
Autor:
Eline L. Hooijman, Valery Radchenko, Sui Wai Ling, Mark Konijnenberg, Tessa Brabander, Stijn L. W. Koolen, Erik de Blois
Publikováno v:
EJNMMI Radiopharmacy and Chemistry, Vol 9, Iss 1, Pp 1-30 (2024)
Abstract Background In the past years, there has been a notable increase in interest regarding targeted alpha therapy using Ac-225, driven by the observed promising clinical anti-tumor effects. As the production and technology has advanced, the avail
Externí odkaz:
https://doaj.org/article/ea3b5e881d0946de8f0c7f54613517f6
Autor:
Sui wai Ling, Astrid A. M. van der Veldt, Mark Konijnenberg, Marcel Segbers, Eline Hooijman, Frank Bruchertseifer, Alfred Morgenstern, Erik de Blois, Tessa Brabander
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-8 (2024)
Abstract Background Life expectancy of patients with metastatic castration-resistant prostate cancer (mCRPC) is still limited despite several systemic treatments. Within five years after diagnosis of primary prostate cancer, 10–20% of the patients
Externí odkaz:
https://doaj.org/article/7895c2af2d0a42f0969b2758f379db83
Autor:
Yulun Wu, Sophie H. A. E. Derks, Tobias C. Wood, Erik de Blois, Astrid A. M. van der Veldt, Marion Smits, Esther A. H. Warnert
Publikováno v:
European Radiology Experimental, Vol 7, Iss 1, Pp 1-12 (2023)
Abstract Background Dynamic glucose-enhanced (DGE) chemical exchange saturation transfer (CEST) has the potential to characterize glucose metabolism in brain metastases. Since the effect size of DGE CEST is small at 3 T (
Externí odkaz:
https://doaj.org/article/c11cb6e1603f42038b963cdfefbb119e
Publikováno v:
EJNMMI Physics, Vol 10, Iss 1, Pp 1-6 (2023)
Abstract Aim To explore the dosimetric effect of substituting Lu-177 with Tb-161 in targeted radionuclide therapy (TRT) using the registered tracers DOTA-TATE and PSMA-617. Methods Using established kinetic data for [177Lu]Lu-DOTA-TATE and [177Lu]Lu-
Externí odkaz:
https://doaj.org/article/3c3bc376cf0c45ed9ebf1e50d3978243
Autor:
Maryana Handula, Savanne Beekman, Mark Konijnenberg, Debra Stuurman, Corrina de Ridder, Frank Bruchertseifer, Alfred Morgenstern, Antonia Denkova, Erik de Blois, Yann Seimbille
Publikováno v:
EJNMMI Radiopharmacy and Chemistry, Vol 8, Iss 1, Pp 1-16 (2023)
Abstract Background The [177Lu]Lu-DOTA-TATE mediated peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors (NETs) is sometimes leading to treatment resistance and disease recurrence. An interesting alternative could be the somatostati
Externí odkaz:
https://doaj.org/article/b4c3e0284752465fa8ed5d7be031a77d
Autor:
Eline L. Hooijman, Carolline M. Ntihabose, Thom G. A. Reuvers, Julie Nonnekens, Else A. Aalbersberg, Jordy R. J. P. van de Merbel, Judith E. Huijmans, Stijn L. W. Koolen, Jeroen J. M. A. Hendrikx, Erik de Blois
Publikováno v:
EJNMMI Radiopharmacy and Chemistry, Vol 7, Iss 1, Pp 1-13 (2022)
Abstract Background Radiopharmaceuticals are considered as regular medicinal products and therefore the same regulations as for non-radioactive medicinal products apply. However, specific aspects should be considered due to the radiochemical properti
Externí odkaz:
https://doaj.org/article/8919aeb2fb114174a30cb978b48e3a49
Publikováno v:
Royal Society Open Science, Vol 10, Iss 3 (2023)
Targeted radionuclide therapy (TRT) is a promising strategy to treat different types of cancer. TRT relies on a targeting vector used to deliver a therapeutic radionuclide specifically to the tumour site. Several low molecular weight ligands targetin
Externí odkaz:
https://doaj.org/article/830b32d9cd5f4dbdbffe95e58abad7ec
Autor:
Dylan Chapeau, Sofia Koustoulidou, Maryana Handula, Savanne Beekman, Corrina de Ridder, Debra Stuurman, Erik de Blois, Yulia Buchatskaya, Karlijn van der Schilden, Marion de Jong, Mark W. Konijnenberg, Yann Seimbille
Publikováno v:
Pharmaceuticals, Vol 16, Iss 7, p 985 (2023)
Peptide receptor radionuclide therapy (PRRT) has been applied to the treatment of neuroendocrine tumors (NETs) for over two decades. However, improvement is still needed, and targeted alpha therapy (TAT) with alpha emitters such as lead-212 (212Pb) r
Externí odkaz:
https://doaj.org/article/b8faf153cecd468bae494dab626614f5
Autor:
Eric J. Meester, Erik de Blois, Boudewijn J. Krenning, Antonius F. W. van der Steen, Jeff P. Norenberg, Kim van Gaalen, Monique R. Bernsen, Marion de Jong, Kim van der Heiden
Publikováno v:
EJNMMI Research, Vol 11, Iss 1, Pp 1-10 (2021)
Abstract Purpose Many radioligands have been developed for the visualization of atherosclerosis by targeting inflammation. However, interpretation of in vivo signals is often limited to plaque identification. We evaluated binding of some promising ra
Externí odkaz:
https://doaj.org/article/565f120e83574cff81d8656dbc65c8a4
Publikováno v:
Pharmaceutics, Vol 14, Iss 10, p 2166 (2022)
For patients with metastatic castration-resistant prostate cancer (mCRPC), the survival benefit of classic treatment options with chemotherapy and drugs targeting androgen signaling is limited. Therefore, beta and alpha radionuclide therapy (RNT) hav
Externí odkaz:
https://doaj.org/article/f9b549a85827455b90197b34f0ab5a5a